Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.91
TKPYY's Cash to Debt is ranked lower than
67% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. TKPYY: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
TKPYY' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 42.61 Max: N/A
Current: 0.91
Equity to Asset 0.50
TKPYY's Equity to Asset is ranked lower than
70% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TKPYY: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
TKPYY' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.76
Current: 0.5
0.5
0.76
F-Score: 3
Z-Score: 2.07
M-Score: -2.73
WACC vs ROIC
6.33%
-4.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -8.78
TKPYY's Operating margin (%) is ranked lower than
79% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. TKPYY: -8.78 )
Ranked among companies with meaningful Operating margin (%) only.
TKPYY' s Operating margin (%) Range Over the Past 10 Years
Min: -7.27  Med: 22.89 Max: 35.13
Current: -8.78
-7.27
35.13
Net-margin (%) -5.91
TKPYY's Net-margin (%) is ranked lower than
78% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. TKPYY: -5.91 )
Ranked among companies with meaningful Net-margin (%) only.
TKPYY' s Net-margin (%) Range Over the Past 10 Years
Min: -8.05  Med: 16.44 Max: 25.85
Current: -5.91
-8.05
25.85
ROE (%) -5.07
TKPYY's ROE (%) is ranked lower than
74% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. TKPYY: -5.07 )
Ranked among companies with meaningful ROE (%) only.
TKPYY' s ROE (%) Range Over the Past 10 Years
Min: -6.33  Med: 11.35 Max: 15.81
Current: -5.07
-6.33
15.81
ROA (%) -2.50
TKPYY's ROA (%) is ranked lower than
73% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. TKPYY: -2.50 )
Ranked among companies with meaningful ROA (%) only.
TKPYY' s ROA (%) Range Over the Past 10 Years
Min: -3.23  Med: 8.64 Max: 12
Current: -2.5
-3.23
12
ROC (Joel Greenblatt) (%) -25.32
TKPYY's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. TKPYY: -25.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TKPYY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.36  Med: 67.64 Max: 210.61
Current: -25.32
-19.36
210.61
Revenue Growth (3Y)(%) 5.80
TKPYY's Revenue Growth (3Y)(%) is ranked higher than
51% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TKPYY: 5.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TKPYY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.2  Med: 4.90 Max: 11.6
Current: 5.8
0.2
11.6
EBITDA Growth (3Y)(%) -28.30
TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TKPYY: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TKPYY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: 1.30 Max: 24.8
Current: -28.3
-28.3
24.8
» TKPYY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.

Ratios

vs
industry
vs
history
Forward P/E 27.03
TKPYY's Forward P/E is ranked lower than
80% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. TKPYY: 27.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.79
TKPYY's P/B is ranked higher than
69% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. TKPYY: 1.79 )
Ranked among companies with meaningful P/B only.
TKPYY' s P/B Range Over the Past 10 Years
Min: 1.22  Med: 1.54 Max: 2.44
Current: 1.79
1.22
2.44
P/S 2.05
TKPYY's P/S is ranked higher than
60% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. TKPYY: 2.05 )
Ranked among companies with meaningful P/S only.
TKPYY' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.21 Max: 12.29
Current: 2.05
1.67
12.29
PFCF 67.90
TKPYY's PFCF is ranked lower than
76% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. TKPYY: 67.90 )
Ranked among companies with meaningful PFCF only.
TKPYY' s PFCF Range Over the Past 10 Years
Min: 10.03  Med: 50.61 Max: 204.92
Current: 67.9
10.03
204.92
POCF 39.81
TKPYY's POCF is ranked lower than
78% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. TKPYY: 39.81 )
Ranked among companies with meaningful POCF only.
TKPYY' s POCF Range Over the Past 10 Years
Min: 7.75  Med: 45.23 Max: 317.13
Current: 39.81
7.75
317.13
EV-to-EBITDA 1713.10
TKPYY's EV-to-EBITDA is ranked lower than
100% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. TKPYY: 1713.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.3  Med: 12.40 Max: 2171.3
Current: 1713.1
3.3
2171.3
Current Ratio 1.53
TKPYY's Current Ratio is ranked lower than
72% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TKPYY: 1.53 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.43 Max: 4
Current: 1.53
1.21
4
Quick Ratio 1.27
TKPYY's Quick Ratio is ranked lower than
68% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. TKPYY: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 2.02 Max: 3.64
Current: 1.27
1
3.64
Days Inventory 185.74
TKPYY's Days Inventory is ranked lower than
79% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. TKPYY: 185.74 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 124.74  Med: 157.06 Max: 180.99
Current: 185.74
124.74
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.69
TKPYY's Dividend Yield is ranked higher than
86% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TKPYY: 1.69 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s Dividend Yield Range Over the Past 10 Years
Min: 1.67  Med: 4.52 Max: 6.48
Current: 1.69
1.67
6.48
Forward Dividend Yield 3.34
TKPYY's Forward Dividend Yield is ranked higher than
84% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TKPYY: 3.34 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.67
TKPYY's Yield on cost (5-Year) is ranked higher than
74% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.95 vs. TKPYY: 1.67 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.67  Med: 4.52 Max: 6.48
Current: 1.67
1.67
6.48
3-Year Average Share Buyback Ratio 0.10
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 425 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. TKPYY: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0.00 Max: 3.9
Current: 0.1
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.87
TKPYY's Price/Tangible Book is ranked lower than
80% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. TKPYY: 7.87 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.85  Med: 6.72 Max: 13.07
Current: 7.87
1.85
13.07
Price/Projected FCF 2.18
TKPYY's Price/Projected FCF is ranked higher than
55% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. TKPYY: 2.18 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.35  Med: 1.73 Max: 2.74
Current: 2.18
1.35
2.74
Price/Median PS Value 0.94
TKPYY's Price/Median PS Value is ranked higher than
69% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. TKPYY: 0.94 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1.00 Max: 5.15
Current: 0.94
0.81
5.15
Earnings Yield (Greenblatt) (%) -3.66
TKPYY's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TKPYY: -3.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.68  Med: 8.30 Max: 23.8
Current: -3.66
-3.68
23.8
Forward Rate of Return (Yacktman) (%) -46.51
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
98% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. TKPYY: -46.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -46.5  Med: -18.60 Max: 15.8
Current: -46.51
-46.5
15.8

More Statistics

Revenue (TTM) (Mil) $15,076
EPS (TTM) $ -0.60
Beta0.36
Short Percentage of Float0.00%
52-Week Range $21.04 - 26.52
Shares Outstanding (Mil)1,572.39

Analyst Estimate

Mar16 Mar17 Mar18
Revenue (Mil $) 16,004 15,236 16,271
EPS ($) 1.14 0.79 1.03
EPS without NRI ($) 1.14 0.79 1.03
EPS Growth Rate
(3Y to 5Y Estimate)
3.14%
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Valeant (VRX) Stock Surges on Rejected Takeda, TPG Bid Speculation May 27 2016
8:31 am Takeda Pharma confirms the EMA's CHMP has adopted a positive opinion for the extension of... May 27 2016
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation... May 27 2016
[$$] Valeant Received Joint Takeover Approach From Takeda, TPG That It Rejected May 27 2016
Takeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in... May 27 2016
Valeant 'Received Bid Proposal' From Takeda, TPG May 27 2016
Valeant rejected joint takeover bid from Takeda, TPG in spring: source May 26 2016
Valeant rejected joint takeover bid from Takeda, TPG in spring - source May 26 2016
Valeant rejected joint takeover bid from Takeda, TPG in spring - source May 26 2016
[$$] Valeant shares rise on reports of rebuffed offer from Takeda May 26 2016
Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ May 26 2016
Valeant Rejected Joint Takeover Approach From Takeda, TPG May 26 2016
Valeant Rises After Reported Rejection of Takeda-TPG Takeover May 26 2016
ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : May 23, 2016 May 23 2016
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week... May 23 2016
Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association (APA) 2016... May 16 2016
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2016 By the Numbers May 12 2016
Takeda Appoints New Chief Financial Officer, James Kehoe May 12 2016
Takeda Reports Results for Fiscal Year 2015 (April 2015 – March 2016) and Forecast for Fiscal Year... May 10 2016
Gates Foundation gives $38M grant to support polio eradication in developing countries May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)